Universität zu Köln

Journal Article

Shitara, Kohei, Ajani, Jaffer A., Moehler, Markus, Garrido, Marcelo, Gallardo, Carlos, Shen, Lin, Yamaguchi, Kensei, Wyrwicz, Lucjan, Skoczylas, Tomasz ORCID: 0000-0002-1276-3828, Bragagnoli, Arinilda Campos, Liu, Tianshu, Tehfe, Mustapha, Elimova, Elena, Bruges, Ricardo, Zander, Thomas, de Azevedo, Sergio, Kowalyszyn, Ruben, Pazo-Cid, Roberto, Schenker, Michael ORCID: 0000-0003-2645-6391, Cleary, James M., Yanez, Patricio, Feeney, Kynan, Karamouzis, Michalis, V, Poulart, Valerie, Lei, Ming, Xiao, Hong, Kondo, Kaoru, Li, Mingshun and Janjigian, Yelena Y. (2022). Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature, 603 (7903). S. 942 - 963. BERLIN: NATURE PORTFOLIO. ISSN 1476-4687

Kelly, Ronan J., Ajani, Jaffer A., Kuzdzal, Jaroslaw, Zander, Thomas, Van Cutsem, Eric, Piessen, Guillaume, Mendez, Guillermo, Feliciano, Josephine, Motoyama, Satoru, Lievre, Astrid, Uronis, Hope, Elimova, Elena, Grootscholten, Cecile, Geboes, Karen, Zafar, Syed, Snow, Stephanie ORCID: 0000-0003-3847-0289, Ko, Andrew H., Feeney, Kynan, Schenker, Michael ORCID: 0000-0003-2645-6391, Kocon, Piotr, Zhang, Jenny, Zhu, Lili, Lei, Ming, Singh, Prianka, Kondo, Kaoru, Cleary, James M. and Moehler, Markus (2021). Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. N. Engl. J. Med., 384 (13). S. 1191 - 1204. WALTHAM: MASSACHUSETTS MEDICAL SOC. ISSN 1533-4406

Janjigian, Yelena Y., Shitara, Kohei, Moehler, Markus, Garrido, Marcelo, Salman, Pamela, Shen, Lin, Wyrwicz, Lucjan ORCID: 0000-0003-0808-6892, Yamaguchi, Kensei, Skoczylas, Tomasz ORCID: 0000-0002-1276-3828, Bragagnoli, Arinilda Campos, Liu, Tianshu, Schenker, Michael ORCID: 0000-0003-2645-6391, Yanez, Patricio, Tehfe, Mustapha, Kowalyszyn, Ruben, Karamouzis, Michalis V., Bruges, Ricardo, Zander, Thomas, Pazo-Cid, Roberto, Hitre, Erika, Feeney, Kynan, Cleary, James M., Poulart, Valerie, Cullen, Dana, Lei, Ming, Xiao, Hong, Kondo, Kaoru, Li, Mingshun and Ajani, Jaffer A. (2021). First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet, 398 (10294). S. 27 - 41. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1474-547X